Physician profile
Timothy J Hoffman
NPI 1417922394
$3,714.39
in general payments reported to CMS, 2019-2025
23 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $274 · 2021: $316 · 2022: $230 · 2023: $557 · 2024: $554 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539 · Education: $17.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.77 |
| Education | $17.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,714.59 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $498.42 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $181.25 | 2019-2025 | Mounjaro, Jardiance |
| Axsome Therapeutics, INC. | $173.05 | 2023-2025 | Auvelity |
| Abbvie INC. | $167.15 | 2025 | |
| Pfizer INC. | $119.83 | 2019-2025 | |
| Amgen INC. | $112.39 | 2020-2025 | Evenity, Prolia |
| Verona Pharma, INC. | $104.41 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $100.22 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $96.26 | 2023-2024 | Trelegy Ellipta |
| Lundbeck LLC | $82.88 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.81 | 2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $46.94 | 2024 | Nuzyra |
| Sanofi Pasteur INC. | $46.00 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $35.76 | 2024 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $22.81 | 2025 | |
| Dexcom, INC. | $21.52 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.90 | 2024 | Tradjenta, Synjardy, Jardiance |
| Ani Pharmaceuticals, INC. | $19.77 | 2025 | Purified Cortrophin Gel |
| Ars Pharmaceuticals Operations, INC. | $18.39 | 2025 | Neffy |
| Abbott Laboratories | $16.82 | 2023 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $13.50 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.